Teresa Amaral

21PUBLICATIONS
71CO-AUTHORS
Environmental epidemiologyRadiation therapyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Nov 06, 2025
Messages for ultraviolet-radiation protection to fair-skinned populations.

Lieve Brochez, Claus Garbe, Teresa Amaral

|Jan 11, 2025
Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669.

Felix Peisen, Annika Gerken, Alessa Hering

|Aug 10, 2024
Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?

Felix Peisen, Annika Gerken, Alessa Hering

|Oct 28, 2023
Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study.

Felix Peisen, Annika Gerken, Alessa Hering

|May 04, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas

|Nov 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Katharina Schumann, Cornelia Mauch, Kai-Christian Klespe

Pageof 4

Frequent Collaborators

6 joint publications

Claus Garbe

6 joint publications

Ulrike Leiter

4 joint publications

Thomas Kurt Eigentler

4 joint publications

Konstantin Nikolaou